Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference
May 08 2019 - 7:00AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that Troy Wilson, Ph.D.,
J.D., President and Chief Executive Officer, is scheduled to
present at the Bank of America Merrill Lynch Health Care Conference
on Tuesday, May 14, 2019 at 2:20 p.m. PT / 5:20 p.m. ET. The
conference will be held May 14-16, 2019 in Las Vegas.
A live audio webcast of the presentation will be available in
the Investors section of Kura’s website at www.kuraoncology.com,
with an archived replay available for 30 days following the
event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s lead drug candidate is tipifarnib, a
farnesyl transferase inhibitor, for which the Company has initiated
a registration-directed trial of tipifarnib in recurrent or
metastatic patients with HRAS mutant HNSCC. In addition, tipifarnib
is being evaluated in multiple other Phase 2 clinical trials in
solid tumor and hematologic indications. Kura’s pipeline also
includes KO-947, an ERK inhibitor, currently in a Phase 1
dose-escalation trial, and KO-539, a menin-MLL inhibitor, which has
been cleared to begin a Phase 1 clinical trial. For additional
information about Kura, please visit the Company’s website at
www.kuraoncology.com.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024